News & Events Upcoming events Oct 21, 2026 - Oct 23, 2026 MSToronto 2026 - 10th Joint ACTRIMS-ECTRIMS Meeting Toronto, Canada More info and meet us there Nov 16, 2026 - Nov 19, 2026 MEDICA 2026 Düsseldorf, Germany More info and meet us there Nov 16, 2026 - Nov 19, 2026 19th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA, United States of America More info and meet us there See all upcoming events Latest news Sep 6, 2011 Press Release: FDA Clears Next-Generation Biomarker Test to Determine Likelihood of Ovarian Cancer in Women Who Present With Adnexal Mass Read more Sep 5, 2011 FDA Clears Next-Generation Biomarker Test to Determine Likelihood of Ovarian Cancer in Women Who Present With Adnexal Mass Read more May 30, 2011 Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer Read more Sep 23, 2010 Fujirebio completed the acquisition of Innogenetics Read more Jul 19, 2010 Fujirebio to acquire Innogenetics from Abbott Read more May 3, 2009 BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management Read more Load More
Oct 21, 2026 - Oct 23, 2026 MSToronto 2026 - 10th Joint ACTRIMS-ECTRIMS Meeting Toronto, Canada More info and meet us there
Nov 16, 2026 - Nov 19, 2026 19th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA, United States of America More info and meet us there
Sep 6, 2011 Press Release: FDA Clears Next-Generation Biomarker Test to Determine Likelihood of Ovarian Cancer in Women Who Present With Adnexal Mass Read more
Sep 5, 2011 FDA Clears Next-Generation Biomarker Test to Determine Likelihood of Ovarian Cancer in Women Who Present With Adnexal Mass Read more
May 30, 2011 Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer Read more
May 3, 2009 BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management Read more
